Showing results (161-170 of 178) with videos related to
Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2019
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 StudyAurelien Marabelle, Dung T Le, Paolo A Ascierto, et al.The Lancet. Oncology|August 11, 2020
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket studySusan M Domchek, Sophie Postel-Vinay, Seock-Ah Im, et al.The Lancet. Oncology|July 17, 2015
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 studyPhilippe A Cassier, Antoine Italiano, Carlos A Gomez-Roca, et al.Cancer Cell|June 6, 2014
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapyCarola H Ries, Michael A Cannarile, Sabine Hoves, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2016
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion StudyLucia Nogova, Lecia V Sequist, Jose Manuel Perez Garcia, et al.Scientific Reports|December 19, 2023
Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activityGrégoire Marret, Stéphane Temam, Maud Kamal, et al.The Lancet. Oncology|April 1, 2024
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trialJean-Pascal Machiels, Yungan Tao, Lisa Licitra, et al.The Lancet. Oncology|August 8, 2020
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 studyXu-Shan Sun, Yungan Tao, Christophe Le Tourneau, et al.Cancer Research Communications|March 27, 2023
Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer ImmunotherapyMichael R Paillasse, Michael Esquerré, Florie A Bertrand, et al.European Journal of Cancer (Oxford, England : 1990)|February 16, 2023
Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trialYungan Tao, Xu-Shan Sun, Yoann Pointreau, et al.Pageof 18